FDA peptide | Pro Health Medicine

top of page

Search

The FDA has announced a significant regulatory update that will impact the peptide market. Several peptides currently classified under Category 2 will be re-evaluated and moved to the Prescription Compounding Advisory Committee (PCAC) for thorough scientific review starting this July.

The FDA has announced a significant regulatory update that will impact the peptide market. Several peptides currently classified under Category 2 will be re-evaluated and moved to the Prescription Compounding Advisory Committee (PCAC) for thorough scientific review starting this July.

FDA to Remove Certain Peptides from Category 2 in 2026 What This Means for Health and Regulation

The FDA’s move to reclassify and review peptides marks a turning point in how these substances are managed. It reflects growing recognition of peptides’ therapeutic potential alongside the need for oversight.

Kristina Reynolds

Apr 164 min read

bottom of page